KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanomaPier Francesco Ferrucci, Paolo A. Ascierto, Paola Queirolo et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 178
KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanomaPaolo A. Ascierto, Antoni Ribas, Pier Francesco Ferrucci et al.|Annals of Oncology|2018Cited by 50
Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in <i>BRAF</i><sup>V600E/K</sup>-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.Antoni Ribas, Paolo A. Ascierto, Pier Francesco Ferrucci et al.|Journal of Clinical Oncology|2022Cited by 8